Virology

Keppler and colleagues show that individuals with hematological cancers rapidly develop potent infection-neutralizing antibodies and a robust T cell response against several SARS-CoV-2 variants of concern in response to mRNA vaccination.

Antibodies that broadly inhibit influenza virus neuraminidase by binding to its active site could be therapeutic candidates, but circulating viruses have acquired a glycosylation site in that region. Here, the authors show that, while the S245N glycosylation site affects binding of tested monoclonal antibodies, protective activity in a mouse model is maintained.

有限公司xsackievirus A16 (CVA-16) causes hand, food and mouth disease in infants and young children, however, currently there are neither anti-virals nor vaccines available for treatment. Here, Zhang et al. characterize two CVA16-specific neutralizing monoclonal antibodies, 9B5 and 8C4. They provide evidence for their prophylactic and therapeutic application in vivo in mice and perform CryoEM to show that both antibodies target different epitopes on the viral capsid.

This Review analyses the possibilities that a nanomedicine approach offers to tackle COVID-19-induced thrombosis and the associated challenges.

In addition to antibody-mediated neutralization, Fc-dependent effector functions of antibodies directed to SARS-CoV-2 are emerging as an important factor in determining the outcome of infection. This Review highlights the current state of the field and discusses remaining uncertainties regarding Fc-dependent, non-neutralizing functions of antibodies.